HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target
Monopar Therapeutics
Monopar Therapeutics MNPR | 0.00 |
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Monopar Therapeutics (NASDAQ:
MNPR) with a Buy and maintains $105 price target.
